• menu
    Market Place Market Place
    Sourcing support Sourcing Support
    API / FDF
    Excipients
    Services
    Developments
    News
    Market Intel
    #Phispers
    #SpeakPharma
    #LearnMore

    NEWS

    DRUGS & DEVELOPMENTS

    MARKET INTEL by PharmaCompass

    AbbVie CDMO has been working with global companies to develop, manufacture & scale biopharmaceutical products.
    All News #Library
    Others

    OS Therapies Reports Strong 1-Year OST-HER2 Trial Data

    BUSINESSWIRE

    OS Therapies Gets FDA Feedback on OST-HER2 Approval Path

    BUSINESSWIRE

    OS Therapies Announces Warrant Exercise & Exchange Offer

    BUSINESSWIRE

    OS Therapies Reports Q1 2025 Results and Business Update

    BUSINESSWIRE

    OS Therapies FDA Meeting Request Granted

    BUSINESSWIRE

    OS Therapies to Attend Jones Healthcare & Tech Innovation Conf.

    BUSINESSWIRE

    OS Therapies Announces Pricing of $6 Million Private Placement

    BUSINESSWIRE

    OS Therapies Reports Q3 2024 Results and Business Update

    BUSINESSWIRE

    OS Therapies Appoints 2 Industry Veterans to Board of Directors

    BUSINESSWIRE

    OS Therapies to Present at H.C. Wainwright Annual Global Investment Conference

    BUSINESSWIRE

    OS Therapies Completes Last Dose In OST-HER2 Osteosarcoma Trial

    BUSINESSWIRE

    OS Therapies Clarifies CUSIP of Common Stock

    BUSINESSWIRE

    OS Therapies Forms Osteosarcoma Patient Advocacy Advisory Board

    BUSINESSWIRE

    OS Therapies Refiles For $6M IPO

    FIERCE BIOTECH

    OS Therapies Prices IPO On NYSE American, To Trade As "OSTX"

    BUSINESSWIRE

    OS Therapies` Positive Resected, Recurrent Osteosarcoma Phase 2b Update

    BUSINESSWIRE

    OS Therapies Announces Full Enrollment in PhIIb Clinical Trial AOST-2121

    BUSINESSWIRE

    OS Therapies Announces Enrollment of Remaining Patients in Phase IIb of OST-HER2

    PRNEWSWIRE

    OS Therapies Receives Rare Pediatric Disease Designation (RDD) OST-HER2

    PRNEWSWIRE

    OS Therapies doses first subject in Phase IIb osteosarcoma therapy trial

    CLINICALTRIALSARENA

    OS Therapies Announces Dosing of First Patient in a Phase IIb Trial of OST-HER2

    PRNEWSWIRE

    OS Therapies Completes $6 Million Series A Funding Round

    PRNEWSWIRE

    OS Therapies Completes $6 Million Series A Funding Round

    PRNEWSWIRE

    OS Therapies Receives Trial Approval From Children`s Oncology Group AOST2121

    PRNEWSWIRE

    Advaxis Announces Receipt of Funding Milestone Payment Under ADXS-HER2

    GLOBENEWSWIRE

    Copyright © 2026 LePro PharmaCompass OPC Private Limited, All rights reserved.